Edgewise Advances Muscle and Heart Disease Pipeline
BOULDER, Colo., May 7, 2026 Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its...
cardiovascular disease
Advertisement
Penumbra Shows Strong Outcomes in STORM-PE Study
Alameda, California | April 13, 2026 Penumbra, Inc. has announced compelling 90-day results from the STORM-PE randomized controlled trial,...
HeartFocus, Inteleos Launch AI Cardiac POCUS Certification
April 7, 2026 — Global HeartFocus, developed by DESKi, in partnership with Inteleos®, has launched the first AI-enabled cardiac...
AliveCor Expands AI Cardiac ECG Technology in Vietnam
MOUNTAIN VIEW, Calif., April 07, 2026 AliveCor Inc., a global leader in AI-powered cardiology solutions, has announced the regulatory...
Anumana Gains FDA Clearance for ECG-AI Amyloidosis Tool
CAMBRIDGE, Mass., April 8, 2026 Anumana, Inc. has received U.S. FDA clearance for its ECG-AI™ algorithm designed to detect...
Advertisements
Affinia Therapeutics Wins Canada Nod for AFTX-201 Trial
Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...
AskBio Completes Phase 2 Enrollment for Heart Failure Gene Therapy
RESEARCH TRIANGLE PARK, N.C., USA, March 31, 2026 AskBio, a wholly owned and independently operated subsidiary of Bayer AG,...
Tenaya–Alnylam $1.13B Deal Targets Heart Disease Genes
South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...
Atom Therapeutics Advances ABP-745 into Phase 2 ASCVD Trial
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
Sharp Therapeutics Advances Toward 2026 Clinical Trials
Pittsburgh, PA & Toronto, ON — November 26, 2025. Sharp Therapeutics Corp. has released its condensed interim consolidated financial...
Advertisement
